First-In-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR In Patients With Advanced Cancer

PURPOSE: To evaluate safety (primary endpoint), tolerability, pharmacokinetics, pharmacodynamic profile, and preliminary activity of the intravenous, pan-class I isoform PI3K/mTOR inhibitor PF-05212384 in patients with advanced solid tumors. EXPERIMENTAL DESIGN: Part 1 of this open-label phase I stu...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Clin Cancer Res
मुख्य लेखकों: Shapiro, Geoffrey I., Bell-McGuinn, Katherine M., Molina, Julian R., Bendell, Johanna C., Spicer, James, Kwak, Eunice L., Pandya, Susan, Millham, Robert, Borzillo, Gary, Pierce, Kristen, Han, Lixin, Houk, Brett, Gallo, Jorge D., Alsina, Maria, Braña, Irene, Tabernero, Josep
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2015
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4508327/
https://ncbi.nlm.nih.gov/pubmed/25652454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1306
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन